Future cancer therapies targeting the Trop-2 protein will likely prioritize strategies that selectively target the “cleaved” or activated form of Trop-2 present in neoplasms [157,158], while sparing the intact form expressed in normal tissues. This evidence concerns the gene TACSTD2 and neoplasm.